Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Selegiline
Published online by Cambridge University Press: 20 February 2025
Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Summary
Selegiline hydrochloride ((R)-(–)-N,α-dimethyl-N-2-propynylphenethylamine hydrochloride) and commonly referred to as l-deprenyl, is a white to near-white crystalline powder, freely soluble in water, with a molecular weight of 223.75 and an empirical formula of C13H17N•HCl.
- Type
- Chapter
- Information
- The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 448 - 458Publisher: Cambridge University PressPrint publication year: 2025
References
Suggested Reading
Cereda, E, Cilia, R, Canesi, M, Tesei, S, Mariani, CB, Zecchinelli, AL, Pezzoli, G. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J Neurol 2017; 264(6): 1254–1263.CrossRefGoogle ScholarPubMed
Fabbrini, G, Abbruzzese, G, Marconi, S, Zappia, M. Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol 2012; 35(3): 134–140.CrossRefGoogle ScholarPubMed
Mizuno, Y, Hattori, N, Kondo, T, Nomoto, M, Origasa, H, Takahashi, R, Yamamoto, M, Yanagisawa, N. Long-term selegiline monotherapy for the treatment of early Parkinson disease. Clin Neuropharmacol 2019; 42(4): 123–130.CrossRefGoogle ScholarPubMed
Tan, Y-Y, Jenner, P, Chen, S-D. Monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease: past, present, and future. J Parkinsons Dis 2022; 12(2): 477–493.CrossRefGoogle ScholarPubMed
References
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 15 May 2022 via www.medicinescomplete.com.Google Scholar
Binde, CD, Tvete, IF, Gåsemyr, JI, Natvig, B, M Klemp, . Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol 2020; 76(12): 1731–1743.CrossRefGoogle ScholarPubMed
Deleu, D, Northway, MG, Hanssens, Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41(4): 261–309.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 15 May 2022 via www.medicinescomplete.com.Google Scholar
Koschel, J, Chaudhuri, KR, Tönges, L, Thiel, M, Raeder, V, Jost, WH. Implications of dopaminergic medication withdrawal in Parkinson’s disease. J Neural Transm (Vienna), 2022; 129(9): 1169–1178.CrossRefGoogle ScholarPubMed
Laine, K, Anttila, M, Huopponen, R, Mäki-Ikola, O, Heinonen, E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 2000; 23(1): 22–27.CrossRefGoogle ScholarPubMed
Nagatsu, T, Sawada, M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells. J Neural Transm Suppl 2006; 2006(71): 53–65.Google Scholar
Selegiline. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 15 May 2022 via www.medicinescomplete.com.Google Scholar
Summary of product characteristics – Eldepryl 10 m tablets. Orion Pharma (UK) Ltd. Electronic Medicines Compendium: Eldepryl 10mg tablets – summary of product characteristics (SmPC) – (emc). Accessed on 15 May 2022 via www.medicines.org.uk.Google Scholar
Tábi, T, Szöko˝, E, Vécsei, L, Magyar, K. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol 2013; 9(5): 629–636.CrossRefGoogle ScholarPubMed